NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer
Executive Summary
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA body NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.
You may also be interested in...
Bruised Roche Wins Another UK Perjeta Round With Price Cut
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary
Roche has praised the flexibility of the UK’s Cancer Drugs Fund, but says NICE cost-effectiveness analysis would be unnecessary if industry rebates fed into a UK drugs budget.
NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut
The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.